Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Baseline characteristics of the study population

From: Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis

Parameter

Before PSM

Pa value

SMD

After PSM

pa value

SMD

SBRT group

(n = 70)

LEN group

(n = 77)

SBRT group

(n = 38)

LEN group

(n = 38)

Gender, n (%)

        

 Male

58 (82.9)

68 (88.3)

0.345

0.169

32 (84.2)

32 (84.2)

1

0

 Female

12 (17.1)

9 (11.7)

  

6 (15.8)

6 (15.8)

  

Age, years, n (%)

        

 < 60 years

26 (37.1)

38 (49.4)

0.136

0.243

18 (47.4)

18 (47.4)

1

0

 ≥ 60 years

44 (62.9)

39 (50.6)

  

20 (52.6)

20 (52.6)

  

Cirrhosis, n (%)

        

 Presence

69 (98.6)

77 (100)

0.476

0

38 (100)

38 (100)

1

0

 Absence

1 (1.4)

0 (0)

  

0 (0)

0 (0)

  

HBV infection, n (%)

        

 Yes

64 (91.4)

73 (94.8)

0.628

0.151

36 (94.7)

37 (94.7)

1

0

 No

6 (8.6)

4 (5.2)

  

2 (5.3)

2 (5.3)

  

Child-Pugh classification, n (%)

        

 A

64 (91.4)

65 (84.4)

0.195

-0.192

36 (94.7)

34 (89.5)

0.674

-0.169

 B

6 (8.6)

12 (15.6)

  

2 (5.3)

4 (10.5)

  

ECOG PS score, n (%)

        

 0

34 (48.6)

32 (41.6)

0.393

-0.141

18 (47.7)

18 (47.7)

1

0

 1

36 (51.4)

45 (58.4)

  

20 (52.6)

20 (52.6)

  

Number Of Tumors, n (%)

        

 ≥ 3

19 (27.1)

40 (51.9)

0.002

0.493

13 (34.2)

13 (34.2)

1

0

 < 3

51 (72.9)

37 (48.1)

  

25 (65.8)

25 (65.8)

  

Tumor size, cm, n (%)

        

 < 5

12 (17.1)

16 (20.8)

0.005

 

8 (21.1)

10 (26.3)

0.79

 

 ≥ 5 and < 10

48 (68.6)

34 (44.2)

 

-0.488

21 (55.3)

21 (55.3)

 

0

 ≥ 10

10 (14.3)

27 (35.1)

 

0.433

9 (23.7)

7 (18.4)

 

-0.134

PVTT, n (%)

        

 Vp1

4 (5.7)

6 (7.8)

0.024

 

2 (5.3)

3 (7.9)

0.939

 

 Vp2

43 (61.2)

28 (36.4)

 

-0.581

16 (42.1)

15 (39.5)

 

-0.053

 Vp3

20 (28.6)

36 (46.8)

 

0.362

17 (44.7)

16 (42.1)

 

-0.053

 Vp4

3 (4.3)

7 (9.1)

 

0.166

3 (7.9)

4 (10.5)

 

0.085

ALBI grade, n (%)

        

 1

20 (28.6)

21 (27.3)

0.861

-0.029

14 (36.8)

12 (31.6)

0.629

-0.112

 2

50 (71.4)

56 (72.7)

  

24 (63.2)

26 (68.4)

  

AFP, n (%)

        

 < 200 ng/mL

33 (47.1)

40 (51.9)

0.561

0.096

21 (55.3)

21 (55.3)

1

0

 ≥ 200 ng/mL

37 (52.9)

37 (48.1)

  

17 (44.7)

17 (44.7)

  

PLT, n (%)

        

 < 100 × 109/L

26 (37.1)

19 (24.7)

0.101

-0.287

9 (23.7)

9 (23.7)

1

0

 ≥ 100 × 109/L

44 (65.9)

58 (75.3)

  

29 (76.3)

29 (76.3)

  

WBC, n (%)

        

 < 4 × 109/L

20 (28.6)

24 (31.2)

0.731

0.056

9 (23.7)

9 (23.7)

1

0

 ≥ 4 × 109/L

50 (71.4)

53 (68.8)

  

29 (76.3)

29 (76.3)

  

Previous treatment, n (%)

        

 Absence

50 (71.4)

68 (88.3)

0.01

-0.522

32 (84.2)

31 (81.6)

0.761

0.067

 Presence

        

 Tace

9 (12.9)

3 (3.9)

  

3 (7.9)

3 (7.9)

  

 Ablation

7 (10.0)

2 (2.6)

  

2 (5.3)

1 (2.6)

  

Argon–Helium cryosurgical

4 (5.7)

4 (5.2)

  

1 (2.6)

3 (7.9)

  
  1. HBV, hepatic B virus; HCV, hepatic C virus; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PVTT, Portal Vein Tumor Thrombosis; ALBI, grade albumin-bilirubin grade; AFP, alpha-fetoprotein; PLT, platelet; WBC, white blood cell; TACE, transarterial chemoembolization; LEN, lenvatinib; SBRT, Stereotactic Body Radiotherapy
  2. a Bold values indicate statistical significance
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us